EPZM

Epizyme, Inc.

NASDAQ

Add Alert

EPZM

Epizyme, Inc.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Enterprising Investor PremiumMember

08/12/22 9:31 AM

Post #104

Expiration of the Offer (8/12/22)

The Offer and all withdrawal rights thereunder expired at 11:59 p.m., Eastern Time, on August 11, 2022 (the “Expiration Time”). Computershare Trust Company, N.A., in its capacity as depositary and paying agent for the Offer (the “Depositary and Paying Agent”), has advised the Parent and the Purchaser that, as of the Expiration Time, a total of 124,185,125 Shares (excluding Shares with respect to which notices of guaranteed delivery were delivered) were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74% of the Shares outstanding as of the Expiration Time. In addition, the Depositary and Paying Agent has advised the Parent and the Purchaser that, as of the Expiration Time, notices of guaranteed delivery had been delivered with respect to 9,299,176 additional Shares, representing approximately 6% of the outstanding Shares as of the Expiration Time.

As of the Expiration Time, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition, and all other conditions to the Offer were satisfied or waived. Accordingly, the Purchaser has accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer and will promptly pay for all such Shares in accordance with the terms of the Offer.

As a result of its acceptance for payment of the Shares validly tendered and not validly withdrawn pursuant to the Offer and in accordance with Section 251(h) of the DGCL, the Purchaser owns at least the percentage of Shares that would be required to adopt the Merger Agreement without a vote of the stockholders of the Company.

Accordingly, the Parent and the Purchaser expect to complete the acquisition of the Company on August 12, 2022 by consummating the Merger pursuant to the Merger Agreement without a vote of the Company’s stockholders in accordance with Section 251(h) of the DGCL. At the Effective Time: (i) the Purchaser shall be merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned indirect subsidiary of Parent, and (ii) each remaining outstanding Share not accepted for payment in the Offer (other than the Excluded Shares) that are issued and outstanding immediately prior to the Effective Time shall be cancelled, shall cease to exist, shall no longer be outstanding, and shall be converted into the right to receive the Offer Price.

Following consummation of the Merger, the Shares will be delisted and will cease to trade on the Nasdaq Stock Market. The Parent and the Purchaser intend to take steps to cause the termination of the registration of the Shares under the Exchange Act and the suspension of all of the Company’s reporting obligations under the Exchange Act as promptly as practicable.”

https://www.sec.gov/Archives/edgar/data/1571498/000119312522219366/d392613dsc14d9a.htm

Pt3

06/27/22 9:52 PM

Post #103

Re: #102: @JJL - 1.45 + 1 = 2.45 Is what I

Thank

JJL

06/27/22 9:47 PM

Post #102

Re: #101: @Pt3 - Jump in blindly what is this buyout 1.45

1.45 + 1 = 2.45 Is what I read. Absolutely crazy volume today!! I'm very puzzled. This morning I didn't get a chance to read it that good but I would say potentially it should be a $2 trade easily? If I didn't think they were going to buy all the shares I would say it's going to go a lot higher? Like $5 at least. Jmo

Pt3

06/27/22 3:48 PM

Post #101

Jump in blindly what is this buyout 1.45 so is my share be ok or loss

JJL

06/27/22 12:38 PM

Post #100

Re: #99: @Pt3 - Ready for what

Retrace

Pt3

06/27/22 12:18 PM

Post #99

Re: #97: @JJL - I'm ready!!

Ready for what

JJL

06/27/22 10:53 AM

Post #98

Re: #95: @Vincent1974 - I have average of 0,59

Nice!

JJL

06/27/22 9:23 AM

Post #97

Re: #96: @Invest-in-America - EPZM: See ya-all up on the MOON by

I'm ready!!

Invest-in-America PremiumMember

06/27/22 9:18 AM

Post #96

EPZM: See ya-all up on the MOON by NY lunchtime, Peeps!!!!

https://pulse2.com/epizyme-epzm-stock-why-it-surged-over-50-today/

Vincent1974 Free

06/26/22 7:14 AM

Post #95

Re: #94: @JJL - Am I the only one on ihub that

I have average of 0,59

JJL

06/24/22 8:13 PM

Post #94

Am I the only one on ihub that loaded up on this? I guess whatever let her run!!!! My gut says this is going over $5. Since my average is 50 cents I damn sure hope I'm right!!

JJL

06/22/22 10:13 PM

Post #93

Re: #92: @SONARSTOCKZ - $EPZM Bottom channel breakout attempt. Increasing momentum. Increasing

It hasn't stopped moving up for sure!!!

SONARSTOCKZ Free

06/14/22 12:10 PM

Post #92

$EPZM Bottom channel breakout attempt. Increasing momentum. Increasing OBV. RSI 55. Need a green close over 50sma for resistance break

JJL

06/08/22 10:28 PM

Post #91

Re: #90: @Engle1488 - Primed and ready for a big run

Yes I just go to figure a good exit point. It should be a lot higher though!! I hope a 10 bag from here. I mean I thought the news a few days ago was good! Seems most cancer patients had good results from their treatment.

Engle1488

06/08/22 10:27 PM

Post #90

Re: #89: @JJL - I completely agree! I loaded!

Primed and ready for a big run

JJL

06/08/22 10:10 PM

Post #89

Re: #88: @Engle1488 - Looking very good last few sessions

I completely agree! I loaded!

Engle1488

06/08/22 4:21 PM

Post #88

Looking very good last few sessions

JJL

06/02/22 10:17 PM

Post #87

When the form fours stop this is going over a dollar

JJL

06/02/22 9:39 PM

Post #86

I added. Good news!

JJL

04/12/22 8:52 PM

Post #85

Re: #76: @ClayTrader - * * $EPZM Video Chart 01-04-2019 * *

Okay, so 7.50 support back then tells me .78 is a screaming buy?? What do I know?

Yordle

02/11/22 11:27 PM

Post #84

Re: #83: @choo choo trader - Is anybody out there still following this ticker?

I'm 3 grand in @1.53 and holding on for dear life.

choo choo trader Free

02/09/22 4:57 PM

Post #83

Is anybody out there still following this ticker? It looks like an insider recently bought 22M shares.

Txguy_01

01/23/20 8:19 PM

Post #82

Re: #81: @JC$ - You'd think it's a no brainer. Usually stocks

Hope it does something tomorrow

JC$

01/23/20 7:34 PM

Post #81

You'd think it's a no brainer. Usually stocks jump on approval... I guess you just have to get through the sell on news/anticipation crowd first.

Txguy_01

01/22/20 3:25 PM

Post #80

Where is this one going tomorrow?

HeadHunter Free

01/06/20 3:59 PM

Post #79

Nice comeback!

jonny_red

12/30/19 11:21 AM

Post #78

3 Healthcare Stocks to Watch With Huge FDA Decisions in January.

$DRRX $AIMT $EPZM

https://www.transparenttradersblackbox.com/post/3-healthcare-stocks-to-watch-with-huge-fda-decisions-in-january-drrx-aimt-epzm

ClayTrader Free

01/04/19 5:21 PM

Post #76

* * $EPZM Video Chart 01-04-2019 * *

Link to Video - click here to watch the technical chart video

crudeoil24 PremiumMember

01/04/19 11:47 AM

Post #75

Re: #74: @crudeoil24 - 7.00 > Epizyme shares are trading higher after

7.20 > tutes pounding the table buying those 100K blocks.

crudeoil24 PremiumMember

01/04/19 10:55 AM

Post #74

7.00 > Epizyme shares are trading higher after the company announced a registration path for Tazemetostate, provided pipeline updates, and stated FY19 guidance."

stockguard Free

09/29/18 1:07 PM

Post #73

Upgrade for October 2nd, 2018

Epizyme analyst commentary at SunTrust Epizyme price target raised to $25 from $20 at SunTrust. SunTrust analyst Peter Lawson raised his price target on Epizyme to $25 and kept his Buy rating, citing the FDA decision for a partial clinical hold lift on tazemetostat enrollment. The analyst notes that the company has not announced any substantial changes to the trial design or patient population, but rather will increase patient monitoring after updating its exclusion criteria for new patient enrollment. Lawson contends that the New Drug Application submission for tazemetostat in the treatment of epithelioid sarcoma expected in the first half of 2019 remains on track.

stockguard Free

09/27/18 1:13 PM

Post #72

Epizyme: An Updated Investment Thesis
Sep. 26, 2018 4:45 PM ET

https://seekingalpha.com/article/4208450-epizyme-updated-investment-thesis

floored

06/15/17 7:44 PM

Post #71

Rumors of a buyout with the favorable clinical trials being announced. Let's face it, this has a ways to go before gains of any longevity can occur and just when it looks possible, the company is bought out. Nice investment with a 12 to 16 month timeline. EPZM

floWteiuQ

09/15/16 11:01 AM

Post #70

Nice EPZM mention here

http://medicalxpress.com/news/2016-09-prospect-shorter-treatment-chronic-myelogenous.htmlice Epizyme mention here:

Yo-Yo

09/12/16 8:01 PM

Post #69

Looks pretty good over here, may have to play a few shares GLTA !!!

floWteiuQ

08/13/16 11:50 AM

Post #68

Re: #67: @trendmkr - Is the Epizyme Dip A Discount Entry Opportunity?

You bet your bippy it is!

trendmkr

08/09/16 2:43 PM

Post #67

Is the Epizyme Dip A Discount Entry Opportunity? http://marketexclusive.com/eyes-epizyme-inc-nasdaqepzm-phase-ii-readout/24197/?icd1

BettingAngles Free

07/18/16 12:08 PM

Post #66

EPZM-Looking to make some traction today..

BettingAngles Free

07/15/16 12:01 PM

Post #65

EPZM-Bouncing

MakinBank

05/23/16 4:47 PM

Post #64

Re: #62: @fl89808 - Price target $32.14!

by who? What do you guys think the pps will if Phase 2 news is good?

floWteiuQ

05/16/16 12:17 PM

Post #63

I think their technology looks promising; therefore, I'm contemplating a small stake, besides bouncing in and out with trading shares.

fl89808

02/04/16 11:04 AM

Post #62

Price target $32.14!

sumotrader Free

01/14/16 1:57 AM

Post #61

Watching EPZM. 60% of the float is short, HUGE insider buys this week.

BettingAngles Free

01/11/16 8:11 AM

Post #60

Year of Biotech's 2016..

BettingAngles Free

01/10/16 9:54 AM

Post #59

http://www.intercooleronline.com/stocks/zacks-investment-research-upgrades-epizyme-inc-epzm-to-buy/327999/

BettingAngles Free

01/08/16 9:22 AM

Post #58

BOUNCE TIME-Part II..

BettingAngles Free

01/07/16 9:18 AM

Post #57

BOUNCE TIME..

stocktrademan Free

07/01/15 11:36 AM

Post #56

$EPZM recent news/filings

bullish

## source: finance.yahoo.com

Mon, 29 Jun 2015 20:44:05 GMT ~ Epizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat (EPZ-6438) at the European Cancer Congress

[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from ...

read full: http://www.noodls.com/view/358420E410FAD6205FD8D7E66BF844A85A90B728
*********************************************************

Mon, 29 Jun 2015 20:34:00 GMT ~ Epizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat (EPZ-6438) at the European Cancer Congress

[Business Wire] - Epizyme, Inc. , a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the phase 1 portion of its ongoing phase 1/2 study of tazemetostat will be presented during the European Cancer Congress 2015, hosted by the European Society of Medical Oncology , to be held in Vienna, Austria, September 25-28, 2015.

read full: http://finance.yahoo.com/news/epizyme-present-clinical-data-ongoing-203400879.html
*********************************************************

Thu, 25 Jun 2015 13:30:01 GMT ~ The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases

read full: http://finance.yahoo.com/news/zacks-analyst-blog-highlights-biomarin-133001320.html
*********************************************************

Wed, 24 Jun 2015 12:44:12 GMT ~ Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog

read full: http://finance.yahoo.com/news/biotech-stock-roundup-biomarin-jumps-124412841.html
*********************************************************

Tue, 23 Jun 2015 15:51:20 GMT ~ Tuesday's Mid-Day Movers: Ambarella Retaliates; Sonic, BlackBerry Hit

read full: http://finance.yahoo.com/news/tuesdays-mid-day-movers-ambarella-155120254.html
*********************************************************

$EPZM charts

basic chart ## source: stockcharts.com

basic chart ## source: stockscores.com

big daily chart ## source: stockcharts.com

big weekly chart ## source: stockcharts.com

$EPZM company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/EPZM/company-info
Ticker: $EPZM
OTC Market Place: Not Available
CIK code: not found
Company name: Epizyme, Inc.
Incorporated In:

Business Description:

$EPZM share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$EPZM extra dd links

Company name: Epizyme, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=EPZM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=EPZM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=EPZM+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/news - http://finance.yahoo.com/q/h?s=EPZM+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/EPZM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=EPZM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/EPZM
DTCC (dtcc.com): http://search2.dtcc.com/?q=Epizyme%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Epizyme%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Epizyme%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/EPZM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=EPZM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=EPZM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=EPZM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=EPZM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=EPZM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=EPZM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=EPZM+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/EPZM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=EPZM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/EPZM.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=EPZM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/EPZM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/EPZM/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/EPZM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/EPZM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/EPZM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=EPZM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=EPZM

$EPZM DD Notes ~ http://www.ddnotesmaker.com/EPZM

investorsito Free

06/22/15 2:19 PM

Post #55

The dumping has begun

investorsito Free

06/22/15 1:13 PM

Post #54

Major correction coming. Shorts will make a killing here

Older

Epizyme, Inc. (EPZM)

Followers	14	Posters	43
Posts (Today)	0	Posts (Total)	104
Created	06/02/13	Type	Free
Moderators

http://www.epizyme.com Overview & History Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. We systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of our product candidates is directed towards patients with a particular genetically defined cancer. Our approach is part of a broader trend towards personalized therapeutics based on first identifying the underlying cause of a disease affecting specific patient populations, applying rational drug design tools to create a therapeutic to bind with a molecular target in the identified disease pathway and using a companion diagnostic to select the right patients for treatment. We have built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic. When Epizyme was founded, we recognized that the HMT class of enzymes might contain many potential oncogenes and, therefore, presented the opportunity to discover, develop and commercialize multiple personalized therapeutics. We have prioritized 20 HMTs as attractive targets for personalized therapeutics based on their oncogenic potential. Our two most advanced therapeutic product programs target the HMTs DOT1L (for the treatment of mixed lineage leukemia, or MLL-r) and EZH2 (for a genetically defined subtype of non-Hodgkin lymphoma). We believe that our ongoing Phase 1 study for EPZ-5676, targeting DOT1L, is the first clinical trial of an HMT inhibitor. We expect to initiate a Phase 1/2 clinical trial of EPZ-6438 targeting EZH2 in 2Q 2013. We were founded in 2007 and are led by a management team with extensive experience in the pharmaceutical industry. We have entered into therapeutic collaborations with Celgene, Eisai and Glaxo Group Limited (an affiliate of GlaxoSmithKline), or GSK, that have provided us with approximately $120 million in non-equity funding through March 31, 2013. As of March 31, 2012, we had $85 million in cash and cash equivalents.